

6th April, 2016

BSE Limited Corporate Relations Department P J Towers, Dalal Street Mumbai 400 001 <u>Scrip Code: 532300</u> Fax Nos: 22723121	National Stock Exchange of India Limited Listing Department Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai 400 051. <u>NSE Symbol – WOCKPHARMA</u> <u>Fax Nos: 26598237 / 26598238</u>
--	--

Dear Sirs,

Sub: Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011

Please find enclosed disclosure in accordance with Regulations 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 for and on behalf of the Promoters, Members of the Promoter Group and Person Acting in Concert ('PAC') for the year ended 31st March, 2016.

Kindly take the same on your records.

Thanking you,

For and on behalf of all Promoters & PAC


Dr. Habil Khorakiwala
Promoter

Encl: As above

CC: Wockhardt Limited
D-4, MIDC, Chikalthana,
Aurangabad - 431006

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part –A- Details of Shareholding

1. Name of the Target Company (TC)		Wockhardt Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed ^s		1.BSE Limited 2. National Stock Exchange of India Limited		
3. Particulars of the shareholder(s): a. Name of person(s) with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the share or voting rights of the TC.		Themisto Trustee Company Private Limited		
or				
b. Name(s) of promoter(s), member of the promoter group and PAC with him.		1. Dr. Habil Khorakiwala 2. Ms. Nafisa Khorakiwala 3. Dr. Huzaifa Khorakiwala 4. Dr. Murtaza Khorakiwala 5. Ms. Zahabiya Khorakiwala 6. Themisto Trustee Company Private Limited 7. Ananke Trustee Company Private Limited 8. Callirhoe Trustee Company Private Limited 9. Pasithee Trustee Company Private Limited 10. Amalthea Consultants 11. Lysithea Consultants 12. HNZ Consultants 13. Humuza Consultants 14. Dartmour Holdings Private Limited 15. Palanpur Holdings and Investments Pvt . Ltd. 16. Khorakiwala Holdings and Investments Pvt Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above		Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on 31 st March, 2016 holding of:				
a)	Shares (Equity)			N.A.
1	Dr. Habil Khorakiwala	4,42,785	0.40	
2	Ms. Nafisa Khorakiwala	2,640	0.00	
3	Dr. Huzaifa Khorakiwala	2,16,000	0.20	
4	Dr. Murtaza Khorakiwala	2,26,200	0.21	

	5	Themisto Trustee Company Private Limited [@]	6,58,97,757	59.63	
	6	Ananke Trustee Company Private Limited [@]	50,00,000	4.52	
	7	Callirhoe Trustee Company Private Limited [@]	50,00,000	4.52	
	8	Pasithe Trustee Company Private Limited [@]	52,00,000	4.71	
	No other Promoter Group Shareholders/ PAC hold shares in Target Company				
b)	Voting Rights (otherwise than by shares)		N.A.	N.A.	N.A.
c)	Warrants		N.A.	N.A.	N.A.
d).	Convertible Securities (OCCRPS): Khorakiwala Holdings and Investments Private Limited (KHIPL) [#]		1,85,28,540	Not ascertainable	Not ascertainable
e).	Any other instrument that would entitle the holder to receive shares in the TC.		N.A.	N.A.	N.A.
Total			Equity Shares: 8,19,85,382	74.19	N.A.
			OCCRPS: 1,85,28,540	Not ascertainable	Not ascertainable

^{\$} Global Depository Receipts (GDRs) of Target Company are listed on Luxembourg Stock Exchange.

[@] The Equity Shares are held by above Trustee Companies on behalf of Partnership Firms.

[#] KHIPL does not hold any Equity Shares in the Target Company. The Target Company has outstanding convertible securities viz. 121,454,927 Optionally Convertible Cumulative Redeemable Preference Shares (OCCRPS), out of which KHIPL holds 18,528,540 Nos. of OCCRP. Further, % of the total shares/ voting rights held by KHIPL, assuming part/ full conversion of OCCRP, is not ascertainable due to following reason:

"As the ratio of conversion of OCCRP into equity shares is dependent on the price to be calculated on the 'Relevant Date', which is future date, it is not possible to ascertain the number of equity shares to be allotted on conversion."